GENELUX (NASDAQ: GNLX) director sells 10,000 shares in Rule 10b5-1 trade

(Neutral)

(Negative)

Form Type

Rhea-AI Filing Summary

GENELUX Corp director Thomas John sold 10,000 shares of Common Stock in an open-market transaction. The sale on June 1, 2026 was made at a weighted average price of $2.9801 per share, with individual prices ranging between $2.94 and $3.05. After the sale, he directly owned 472,784 shares. The transaction was carried out pursuant to a Rule 10b5-1 trading plan adopted on June 4, 2025, indicating it was pre-arranged under SEC rules rather than timed discretionarily.

Insights

Small Rule 10b5-1 sale; routine disposition with large remaining stake.

The filing shows director Thomas John executed an open-market sale of 10,000 GENELUX Corp shares at a weighted average of $2.9801 on June 1, 2026. Following the trade, he still holds 472,784 shares directly.

The transaction occurred under a Rule 10b5-1 trading plan adopted on June 4, 2025, meaning the sale schedule was set in advance. Such plans are designed to separate trading decisions from day-to-day information flows, so the timing carries limited informational value.

The sale represents a small portion of the reported post-transaction holdings, which makes this look like a routine liquidity or diversification event rather than a major repositioning. Subsequent Form 4 filings will give a fuller picture of any ongoing pattern under this plan.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Thomas John

Role Director

Sold 10,000 shs ($30K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$2.9801	$30K

Holdings After Transaction: Common Stock — 472,784 shares (Direct)

Footnotes (2)

F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025.
F2. The weighted average sale price for the transaction reported was $2.9801, and the range of prices were between $2.94 and $3.05. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 10,000 shares Weighted average sale price: $2.9801 per share Post-transaction holdings: 472,784 shares +3 more

6 metrics

Shares sold 10,000 shares Open-market sale of Common Stock on June 1, 2026

Weighted average sale price $2.9801 per share June 1, 2026 Common Stock sale

Post-transaction holdings 472,784 shares Common Stock directly owned after sale

Price range of trades $2.94–$3.05 per share Range for individual sale executions on June 1, 2026

Transaction code S (sale in open market or private transaction) Form 4 non-derivative transaction classification

Trading plan adoption date June 4, 2025 Rule 10b5-1 trading plan used for this sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $2.9801, and the range of prices were between $2.94 and $3.05."

open-market sale financial

"transaction_action: "open-market sale" and transaction_code_description: "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/02/2026 - 08:35 PM Accepted by SEC EDGAR 06/02/2026 - 08:35 PM

FAQ

What did GENELUX Corp (GNLX) director Thomas John report in this Form 4?

Thomas John reported selling 10,000 shares of GENELUX Corp Common Stock. The open-market transaction occurred on June 1, 2026 at a weighted average price of $2.9801 per share, leaving him with 472,784 shares directly owned after the sale.

At what price did Thomas John sell GENELUX (GNLX) shares in this Form 4?

He sold the 10,000 GENELUX shares at a weighted average price of $2.9801 per share. The filing states individual trade prices ranged from $2.94 to $3.05, and full price-by-lot details are available on request from the issuer, SEC staff, or any security holder.

How many GENELUX (GNLX) shares does Thomas John own after the reported sale?

After the reported transaction, Thomas John directly holds 472,784 shares of GENELUX Common Stock. This post-transaction balance, disclosed in the Form 4, shows he retained a substantial equity position despite the 10,000-share open-market sale reported for June 1, 2026.

Was the GENELUX (GNLX) insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Thomas John on June 4, 2025. Such plans pre-schedule trades under SEC rules, reducing the significance of any apparent timing in the June 1, 2026 sale.

What type of transaction is reported for GENELUX (GNLX) in this insider filing?

The filing reports an open-market sale of Common Stock, coded as “S” on Form 4. It is a non-derivative transaction involving 10,000 shares, with the transaction description noting a sale in open market or private transaction, rather than an option exercise or derivative-related event.

Does this GENELUX (GNLX) Form 4 show any derivative securities or option exercises?

No derivative transactions are listed in this Form 4 excerpt. The derivativeSummary section is empty, and the only reported activity is the non-derivative open-market sale of 10,000 shares of Common Stock, leaving 472,784 Common Stock shares directly owned afterward.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thomas John

(Last)

(First)

(Middle)

C/O GENELUX CORPORATION

2625 TOWNSGATE ROAD, SUITE 230

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91361

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		S⁽¹⁾		10,000	D	$2.9801⁽²⁾	472,784	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025.

2. The weighted average sale price for the transaction reported was $2.9801, and the range of prices were between $2.94 and $3.05. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Thomas Zindrick, J.D., Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR